These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 33035672)

  • 21. Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.
    Charlton CL; Nguyen LT; Bailey A; Fenton J; Plitt SS; Marohn C; Lau C; Hinshaw D; Lutsiak C; Simmonds K; Kanji JN; Zelyas N; Lee N; Mengel M; Tipples G
    Microbiol Spectr; 2021 Sep; 9(1):e0029121. PubMed ID: 34406813
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Analysis of Nucleic Acid and Antibody Detection Results for SARS-CoV-2 Infection.
    Chen J; Niu Z; Li H; Tang D; Zhang P
    Arch Iran Med; 2021 May; 24(5):427-433. PubMed ID: 34196209
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Unexpected high frequency of unspecific reactivities by testing pre-epidemic blood specimens from Europe and Africa with SARS-CoV-2 IgG-IgM antibody rapid tests points to IgM as the Achilles heel.
    Mboumba Bouassa RS; Péré H; Tonen-Wolyec S; Longo JD; Moussa S; Mbopi-Keou FX; Mossoro-Kpinde CD; Grésenguet G; Veyer D; Bélec L
    J Med Virol; 2021 Apr; 93(4):2196-2203. PubMed ID: 33107601
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Seroprevalence of immunoglobulin M and G antibodies against SARS-CoV-2 in China.
    Xu X; Sun J; Nie S; Li H; Kong Y; Liang M; Hou J; Huang X; Li D; Ma T; Peng J; Gao S; Shao Y; Zhu H; Lau JY; Wang G; Xie C; Jiang L; Huang A; Yang Z; Zhang K; Hou FF
    Nat Med; 2020 Aug; 26(8):1193-1195. PubMed ID: 32504052
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Seroprevalence of SARS-CoV-2 in Bhubaneswar, India: findings from three rounds of community surveys.
    Kshatri JS; Bhattacharya D; Praharaj I; Mansingh A; Parai D; Kanungo S; Palo SK; Giri S; Pattnaik M; Barik SR; Dash GC; Choudhary HR; Turuk J; Mandal NN; Pati S
    Epidemiol Infect; 2021 Apr; 149():e139. PubMed ID: 33902776
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Low prevalence of antibodies against SARS-CoV-2 among voluntary blood donors in Guangzhou, China.
    Xu R; Huang J; Duan C; Liao Q; Shan Z; Wang M; Rong X; Li C; Fu Y; Wang H
    J Med Virol; 2021 Mar; 93(3):1743-1747. PubMed ID: 32813273
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prevalence of SARS-CoV-2 Infection in Children and Their Parents in Southwest Germany.
    Tönshoff B; Müller B; Elling R; Renk H; Meissner P; Hengel H; Garbade SF; Kieser M; Jeltsch K; Grulich-Henn J; Euler J; Stich M; Chobanyan-Jürgens K; Zernickel M; Janda A; Wölfle L; Stamminger T; Iftner T; Ganzenmueller T; Schmitt C; Görne T; Laketa V; Olberg S; Plaszczyca A; Cortese M; Bartenschlager R; Pape C; Remme R; Huzly D; Panning M; Weigang S; Giese S; Ciminski K; Ankerhold J; Kochs G; Schwemmle M; Handgretinger R; Niemeyer CM; Engel C; Kern WV; Hoffmann GF; Franz AR; Henneke P; Debatin KM; Kräusslich HG
    JAMA Pediatr; 2021 Jun; 175(6):586-593. PubMed ID: 33480966
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The seroprevalence and kinetics of IgM and IgG in the progression of COVID-19.
    Qin X; Shen J; Dai E; Li H; Tang G; Zhang L; Hou X; Lu M; Wu X; Duan S; Zhang J; Tsoi MF; Jiang P; Li Y
    BMC Immunol; 2021 Feb; 22(1):14. PubMed ID: 33596826
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Surveillance of SARS-CoV-2 antibodies of patients in the local affected area during Wuhan lockdown.
    Tang Y; Sun J; Yuan Y; Yao F; Zheng B; Yang G; Xie W; Ye G; Li Z; Jiao X; Li Y
    BMC Infect Dis; 2022 Jan; 22(1):10. PubMed ID: 34983429
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prevalence and associated characteristics of anti-SARS-CoV-2 antibodies in Mexico 5 months after pandemic arrival.
    Díaz-Salazar C; Sánchez-García A; Rodríguez-Gutiérrez R; Camacho-Ortiz A; Saldívar-Rodríguez D; González-González JG
    BMC Infect Dis; 2021 Aug; 21(1):835. PubMed ID: 34412620
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Estimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England.
    Wells PM; Doores KJ; Couvreur S; Nunez RM; Seow J; Graham C; Acors S; Kouphou N; Neil SJD; Tedder RS; Matos PM; Poulton K; Lista MJ; Dickenson RE; Sertkaya H; Maguire TJA; Scourfield EJ; Bowyer RCE; Hart D; O'Byrne A; Steel KJA; Hemmings O; Rosadas C; McClure MO; Capedevilla-Pujol J; Wolf J; Ourselin S; Brown MA; Malim MH; Spector T; Steves CJ
    J Infect; 2020 Dec; 81(6):931-936. PubMed ID: 33068628
    [TBL] [Abstract][Full Text] [Related]  

  • 32. SARS-CoV-2 seroprevalence, and IgG concentration and pseudovirus neutralising antibody titres after infection, compared by HIV status: a matched case-control observational study.
    Spinelli MA; Lynch KL; Yun C; Glidden DV; Peluso MJ; Henrich TJ; Gandhi M; Brown LB
    Lancet HIV; 2021 Jun; 8(6):e334-e341. PubMed ID: 33933189
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High SARS-CoV-2 IgG/IGM seroprevalence in asymptomatic Congolese in Brazzaville, the Republic of Congo.
    Batchi-Bouyou AL; Lobaloba Ingoba L; Ndounga M; Vouvoungui JC; Mfoutou Mapanguy CC; Boumpoutou KR; Ntoumi F
    Int J Infect Dis; 2021 May; 106():3-7. PubMed ID: 33370565
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Provider Antibody Serology Study of Virus in the Emergency Room (PASSOVER) Study: Special Population COVID-19 Seroprevalence.
    Heyming TW; Sanger T; Tongol A; Schomberg J; Bacon K; Lara B
    West J Emerg Med; 2021 Apr; 22(3):565-571. PubMed ID: 34125028
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of Clinical and Epidemiological Characteristics of Asymptomatic and Symptomatic SARS-CoV-2 Infection in Children.
    Cai J; Wang X; Zhao J; Ge Y; Xu J; Tian H; Chang H; Xia A; Wang J; Zhang J; Wei Z; Li J; Wang C; Wang J; Zhu Q; Zhai X; Zeng M
    Virol Sin; 2020 Dec; 35(6):803-810. PubMed ID: 33146873
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Seroprevalence of Immunoglobulin M and G Antibodies against SARS-CoV-2 Virus: A Systematic Review and Meta-Analysis Study.
    Fathi M; Vakili K; Sayehmiri F; Mohamadkhani A; Ghanbari R; Hajiesmaeili M; Rezaei-Tavirani M
    Iran J Immunol; 2021 Mar; 18(1):34-46. PubMed ID: 33787512
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Seroprevalence of Unidentified SARS-CoV-2 Infection in Hong Kong During 3 Pandemic Waves.
    Boon SS; Wong MCS; Ng RWY; Leung DTM; Chen Z; Lai CKC; Ho WCS; Huang J; Wong BKC; Fung KSC; Chan PKS
    JAMA Netw Open; 2021 Nov; 4(11):e2132923. PubMed ID: 34779848
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Persistence of SARS-CoV-2-Specific Antibodies for 13 Months after Infection.
    Kučinskaitė-Kodzė I; Simanavičius M; Šimaitis A; Žvirblienė A
    Viruses; 2021 Nov; 13(11):. PubMed ID: 34835119
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevalence of SARS-CoV-2 IgG antibodies in an area of northeastern Italy with a high incidence of COVID-19 cases: a population-based study.
    Stefanelli P; Bella A; Fedele G; Pancheri S; Leone P; Vacca P; Neri A; Carannante A; Fazio C; Benedetti E; Fiore S; Fabiani C; Simmaco M; Santino I; Zuccali MG; Bizzarri G; Magnoni R; Benetollo PP; Merler S; Brusaferro S; Rezza G; Ferro A
    Clin Microbiol Infect; 2021 Apr; 27(4):633.e1-633.e7. PubMed ID: 33253941
    [TBL] [Abstract][Full Text] [Related]  

  • 40. SARS-CoV-2 antibody kinetics in blood donors with a previously positive SARS-CoV-2 antibody test within a seroprevalence survey.
    Levring MB; Holm DK; Nilsson AC; Bauer JM; Jensen IS; Davidsen JR; Rasmussen LD; Sprogøe U; Lillevang ST
    J Med Virol; 2022 Apr; 94(4):1711-1716. PubMed ID: 34845745
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.